TIGIT and Miyoshi myopathy: Anti-TIGIT monoclonal antibody decreased myeloma cells in bone marrow and prolonged survival compared with control-Ig or anti-PD-1 monoclonal antibody-treated mice [103], suggesting that TIGIT expression is more dominant than PD-1 in the immunosuppressive function in MM.